Danish biotech firm Advandx gets DKK 42 million cash injection  

2009.08.25
Advandx, which develops and markets molecular-based diagnostic products for infectious diseases, has gained around DKK 42m in fresh capital from existing investors
The Danish biotech company Advandx, which develops and markets molecular-based diagnostic products for infectious diseases, has gained around DKK 42m (USD 8m) in fresh capital from existing investors SLS Venture and LD Pension, reports financial daily newspaper Børsen.
 
The new cash resources will be used both to finance the company's international sales and marketing, and to continue development of its molecular diagnostic products.
 
“We continue to see increased adoption of our clinical diagnostic products and this latest financing will
enable us to add new tests to our product portfolio and to continue to expand our customer base. We
greatly appreciate our investors’ strong commitment to Advandx and our future,” writes Advandx CEO Thais T. Johansen in a company press release.
 
Advandx also announced the election to the board of Tina W. Christensen, who is CFO of the Danish health insurance company Danmark which provides supplemental health insurance to 2 million Danish citizens.
 
Link > Advandx                    

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×